Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus

Journal of Diabetes

Volumn 6, Issue 2, 2014, Pages 176-183

  Dailey, George ^a   Aurand, Lisa ^b   Stewart, John ^e   Ameer, Barbara ^c   Zhou, Rong ^d  

^a SCRIPPS CLINIC   (United States)

^b SANOFI   (France)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Medpace ^*  (United States)

^e Sanofi Canada   (Canada)

Author keywords

Algorithm; Insulin glargine; Titration; Type 2 diabetes

Indexed keywords

ALGORITHM; INSULIN GLARGINE; TITRATION; TYPE 2 DIABETES;

AGED; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84895072081     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12080     Document Type: Article

References (23)

1. Inzucchi SE, Bergenstal RM, Buse JB etal. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
2. Wright A, Burden ACF, Paisey RB etal. Sulfonylurea inadequacy. Diabetes Care. 2002; 25: 330-336.
3. Nathan DM, Buse JB, Davidson MB etal. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29: 1963-1972.
4. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol. 2007; 1: 540-548.
5. Unger J. Comparing the efficacy, safety, and utility of intensive insulin algorithms for a primary care practice. Diabetes Ther. 2011; 2: 40-50.
6. Gerstein HC, Yale JF, Harris SB etal. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006; 23: 736-742.
7. Yki-Järvinen H, Juurinen L, Alvarsson M etal. Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007; 30: 1364-1369.
8. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-3086.
9. Rosenstock J, Sugimoto D, Strange P etal. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006; 29: 554-559.
10. Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract. 2010; 16: 588-599.
11. Sanofi-Aventis. Lantus versus humalog mix as add-on therapy in type 2 diabetes patients failing sulfonylurea and metformin combination treatment. 2001. Trial identifier: NCT01336751. Available from: http://clinicaltrials.gov/ct2/show/NCT01336751
12. Janka HU, Plewe G, Riddle MC etal. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005; 28: 254-259.
13. Bretzel RG, Nuber U, Landgraf W etal. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet. 2008; 371: 1073-1084.
14. Davies M, Storms F, Shutler S etal. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care. 2005; 28: 1282-1288.
15. Harris S, Yale J-F, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully? Can Fam Physician. 2008; 54: 550-558.
16. TM 303 study. Diabetes Obes Metab. 2007; 9: 902-913.
17. Barnett A. Dosing of insulin glargine in the treatment of type 2 diabetes. Clin Ther. 2007; 29: 987-999.
18. Rakel RE. Improving patient acceptance and adherence in diabetes management: A focus on insulin therapy. Adv Ther. 2009; 26: 838-846.
19. LaSalle JR. Empowering patients during insulin initiation: A real-world approach. J Am Osteopath Assoc. 2010; 110: 69-78.
20. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care. 2005; 28: 2543-2545.
21. Peyrot M, Rubin RR, Lauritzen T etal. International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28: 2673-2679.
22. Rubin RR, Peyrot M, Siminerio LM. International DAWN advisory panel. Health care and patient-reported outcomes. Diabetes Care. 2006; 29: 1249-1255.
23. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29: 682-689.